Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice

J Infect Dis. 2003 Nov 15;188(10):1605-9. doi: 10.1086/379153. Epub 2003 Oct 23.

Abstract

We hypothesized that orally administered, recombinant class A beta-lactamase would inactivate the portion of parenteral piperacillin excreted into the intestinal tract, preserving colonization resistance of mice against nosocomial pathogens. Subcutaneous piperacillin or piperacillin plus oral beta-lactamase were administered 24 and 12 h before orogastric inoculation of piperacillin-resistant pathogens. Oral administration of beta-lactamase reduced piperacillin-associated alteration of the indigenous microflora and prevented overgrowth of pathogens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Candida glabrata / genetics
  • Candida glabrata / metabolism
  • Candidiasis / drug therapy
  • Community-Acquired Infections / drug therapy
  • Cross Infection / drug therapy
  • DNA, Bacterial / chemistry
  • DNA, Bacterial / genetics
  • DNA, Fungal / chemistry
  • DNA, Fungal / genetics
  • Drug Synergism
  • Enterococcus faecium / genetics
  • Enterococcus faecium / metabolism
  • Feces / microbiology
  • Female
  • Gram-Positive Bacterial Infections / drug therapy
  • Klebsiella Infections / drug therapy
  • Klebsiella pneumoniae / genetics
  • Klebsiella pneumoniae / metabolism
  • Mice
  • Piperacillin / pharmacokinetics
  • Piperacillin / pharmacology*
  • Polymerase Chain Reaction
  • beta-Lactam Resistance / drug effects
  • beta-Lactamases / pharmacology*

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial
  • DNA, Fungal
  • beta-Lactamases
  • Piperacillin